Comment
. 2004 Mar 1;103(5):1966-7; author reply 1967.
doi: 10.1182/blood-2003-10-3475.
Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo
- PMID: 14976062
- DOI: 10.1182/blood-2003-10-3475
Item in Clipboard
Comment
Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo
Blood.
.
Free article
No abstract available
Comment on
-
Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.Blood. 2004 Jan 15;103(2):538-44. doi: 10.1182/blood-2003-03-0975. Epub 2003 Sep 22. Blood. 2004. PMID: 14504105
Similar articles
-
Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.Blood. 2004 Jan 15;103(2):538-44. doi: 10.1182/blood-2003-03-0975. Epub 2003 Sep 22. Blood. 2004. PMID: 14504105
-
[Effects of Imatinib mesylate on the development of dendritic cells derived from bone marrow mononuclear cells of patients with chronic myeloid leukemia].Zhonghua Yi Xue Za Zhi. 2006 Aug 29;86(32):2252-5. Zhonghua Yi Xue Za Zhi. 2006. PMID: 17064569 Chinese.
-
BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.Blood. 2004 Apr 15;103(8):3167-74. doi: 10.1182/blood-2003-04-1271. Epub 2003 Dec 11. Blood. 2004. PMID: 15070699
-
Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells.Leuk Lymphoma. 2004 Feb;45(2):237-45. doi: 10.1080/1042819031000151905. Leuk Lymphoma. 2004. PMID: 15101707 Review.
-
Imatinib mesylate in the treatment of chronic myeloid leukaemia.Expert Opin Pharmacother. 2003 Jun;4(6):963-71. doi: 10.1517/14656566.4.6.963. Expert Opin Pharmacother. 2003. PMID: 12783592 Review.
Cited by
-
Cytokine Syntheses by T-Cell Subsets From Chronic Myeloid Leukemia Patients: Relationship Between Pre-Treatment Levels and Response to Imatinib Therapy.J Hematol. 2018 Sep;7(3):96-106. doi: 10.14740/jh410w. Epub 2018 Sep 1. J Hematol. 2018. PMID: 32300421 Free PMC article.
-
Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia.Int J Hematol. 2023 Apr;117(4):613-617. doi: 10.1007/s12185-022-03492-9. Epub 2022 Nov 14. Int J Hematol. 2023. PMID: 36374396 Free PMC article.
-
Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.J Immunol. 2008 Nov 15;181(10):6955-63. doi: 10.4049/jimmunol.181.10.6955. J Immunol. 2008. PMID: 18981115 Free PMC article.
-
Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia.Cancer Immunol Immunother. 2005 Apr;54(4):297-306. doi: 10.1007/s00262-004-0573-1. Epub 2004 Nov 30. Cancer Immunol Immunother. 2005. PMID: 15692843 Free PMC article. Review.
-
Immune modulation by dendritic-cell-based cancer vaccines.J Biosci. 2017 Mar;42(1):161-173. doi: 10.1007/s12038-017-9665-x. J Biosci. 2017. PMID: 28229976 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
